Kisspeptin-10

Published · Researched 2026-09-21

Category: Libido, Tanning, Sleep & Niche · Research date: 2026-09-20 · Slug: kisspeptin-10

Overview

Kisspeptin-10 (KP-10, metastin 45–54) is a synthetic decapeptide fragment of the kisspeptin family — the upstream neuropeptide signal that drives hypothalamic GnRH release and, downstream of that, LH/FSH and sex-steroid production. In 2026 it circulates in biohacking and libido-peptide circles as a research compound discussed for low motivation, low libido, and hormonal-axis signaling, most often sold as 5 mg lyophilized vials from research-peptide vendors. The single most repeated community criticism is its very short half-life, which skeptics cite as the reason KP-10 never became a practical therapeutic despite real upstream biology. It is frequently name-paired with PT-141 in women's libido discussions.

Social standing

Threads: Direct owner signal is thin but present. A May 31, 2026 thread had a user asking whether any women had started Kisspeptin — a genuine newcomer/experience-seeking question that drew engagement. @privintel (TheBioArchitect, 2026-07-03) discussed PT-141 alongside kisspeptin for female HSDD after GLP-1/weight-loss, a pairing framing echoed across women's-health threads. Otherwise the peptide shows up mostly as generic supplier chatter rather than experience reports.

Instagram: The liveliest layer, but ad-heavy. @brendanpaul.a (2026-07-14) promoted Kisspeptin alongside retatrutide for low motivation/libido; comments were mixed — sourcing and dosing requests alongside open skepticism about Kisspeptin-10's short half-life. @rachelokinsfit (2026-07-15) covered the same trend. This is biohacker-influencer content, not neutral medical consensus, and should be read as marketing-adjacent.

Facebook: No verified item-level discussion was found in the surveyed groups (Peptides – information. Education. and sharing (1,000 members), Peptide Community 101 (878), Biohacking, Longevity, CRISPR, Supplements, Life Extension, Wim Hof (10,000)) — direct Kisspeptin queries returned zero posts. This is the main reason the item does not reach Tier 1.

Recurring praise: upstream mechanism (acts at the top of the reproductive axis rather than downstream); interest for libido/motivation, especially in women post-weight-loss.

Recurring complaints: short half-life makes it impractical (the dominant criticism); sourcing/dosing questions dominate over actual experience reports; much of the visible content is influencer promotion rather than owner evidence.

Social validation

Tier: Tier 2 — genuine social signal on Instagram and Threads, but no verified Facebook-group item discussion and a heavy ad/influencer skew.

Named sources and what each proves:

  • Instagram @brendanpaul.a (2026-07-14) — proves Kisspeptin's 2026 biohacking-trend status (paired with retatrutide for motivation/libido) and documents the community's half-life skepticism in comments.
  • Instagram @rachelokinsfit (2026-07-15) — proves the same trend was being pushed by multiple fitness creators simultaneously (coordinated-hype signal, not independent evidence).
  • Threads @privintel (2026-07-03) — proves the PT-141 + kisspeptin pairing frame in women's HSDD discussion.
  • Threads (2026-05-31 user thread) — proves genuine newcomer curiosity ("have any women started Kisspeptin?") rather than vendor-seeded content.

Key specs table

Spec Detail
Identity Kisspeptin-10 (KP-10), metastin fragment 45–54, synthetic decapeptide
Sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (as catalog-listed by vendors)
Formula / MW C63H83N17O14 · ~1302.5 g/mol · CAS 374675-21-5 (as catalog-listed; primary-source verification not performed)
Target KISS1R (GPR54) — upstream of hypothalamic GnRH release
Vial sizes (grey market) 5 mg lyophilized per vial (standard)
Half-life Frequently described as minutes-scale in community/vendor copy — UNVERIFIED; no primary pharmacokinetic source confirmed in this pass
Community-reported research use Sourcing and dosing questions dominate discussion; no verified community dosing consensus was observed in this pass. Reported behavior only — not instructions.
Storage Lyophilized: −20 °C long-term (vendors also state RT stable ~90 days); reconstituted: 2–8 °C, short use window; avoid freeze–thaw

Pricing

All prices observed 2026-09-20 from research-peptide vendor listings (grey market, research-use-only), 5 mg vials unless noted.

Vendor / source Price Notes
CoreVionRX $75 (5 mg) single-vial listing
Market dataset (multi-vendor) median $6.65/mg, high $9.60/mg ≈ $33–$48 per 5 mg at median; one obvious anomalous/outlier row excluded as untrustworthy
Cayman/Biomol (reagent grade) €87 (1 mg) / €359 (5 mg) / €549 (10 mg) lab-reagent pricing, not grey-market street pricing
  • Street range: roughly $33–$75 per 5 mg vial depending on vendor tier.
  • Facebook Marketplace: not searched in this pass — used-value range UNVERIFIED.
  • Exact stock/availability at time of writing: UNVERIFIED.

What's included / what's needed

Vial listings ship the lyophilized 5 mg vial only (some vendors add a per-lot COA). Needed separately per community practice: bacteriostatic water, insulin syringes for subcutaneous use. No kit-style bundles were observed as standard for this item.

Support reality

No manufacturer warranty exists on research vials; vendor satisfaction guarantees (where advertised) are vendor policies, not enforceable warranties, with mixed community reporting on honoring. No independent certification body exists — per-lot third-party COAs are the community's only quality instrument, and the standing advice is to demand them. Ad-heavy influencer promotion around Kisspeptin in 2026 shows weak organic interest relative to its hype volume — treat influencer-driven visibility as a negative reliability signal, not validation.

Community verdict

Kisspeptin-10 has real upstream biology and genuine curiosity behind it — especially the PT-141 pairing frame for women's libido — but the community's dominant note is skepticism: the short half-life criticism appears in nearly every serious discussion, experience reports are scarce relative to promotional content, and no Facebook-group dosing culture was observed. It reads as a trend ingredient rather than a community-validated staple.

Regulatory & safety status

  • No FDA or EMA approval for kisspeptin-10 for any human use. It is a research compound; this status was consistent across all sources checked.
  • Human kisspeptin research exists in academic/clinical-trial settings (reproductive endocrinology), but that does not transfer to grey-market vials in any form.
  • Safety profile in self-administered use: UNVERIFIED — no reliable community adverse-event consensus was observed; absence of reports is not evidence of safety.

Image views

6 of 8 views obtained (vendor product images, JPEG). The "top-angle" and "real-owner-in-use" views were unavailable; no verifiable real-owner product photos of Kisspeptin-10 vials were found.

  • hero: img/kisspeptin-10-hero.jpg
  • side-profile: img/kisspeptin-10-side-profile.jpg
  • rear: img/kisspeptin-10-rear.jpg
  • detail: img/kisspeptin-10-detail.jpg
  • scale: img/kisspeptin-10-scale.jpg
  • box-accessories: img/kisspeptin-10-box-accessories.jpg
  • top-angle: unavailable — no distinct top-view vendor image found
  • real-owner-in-use: unavailable — no verifiable real-owner product photos found

Not medical advice. This is research documentation only. Kisspeptin-10 is an unapproved research compound; consult a licensed healthcare provider.

Kisspeptin-10 — box-accessories view
box-accessories view Original vendor page URL not recorded in research dossier
Kisspeptin-10 — detail view
detail view Original vendor page URL not recorded in research dossier
Kisspeptin-10 — hero view
hero view Original vendor page URL not recorded in research dossier
Kisspeptin-10 — rear view
rear view Original vendor page URL not recorded in research dossier
Kisspeptin-10 — scale view
scale view Original vendor page URL not recorded in research dossier
Kisspeptin-10 — side-profile view
side-profile view Original vendor page URL not recorded in research dossier

Named sources

  • Instagram @brendanpaul.a (2026-07-14) — proves Kisspeptin's 2026 biohacking-trend status (paired with retatrutide for motivation/libido) and documents the community's half-life skepticism in comments. (2026-07-14)
  • Instagram @rachelokinsfit (2026-07-15) — proves the same trend was being pushed by multiple fitness creators simultaneously (coordinated-hype signal, not independent evidence). (2026-07-15)
  • Threads @privintel (2026-07-03) — proves the PT-141 + kisspeptin pairing frame in women's HSDD discussion. (2026-07-03)
  • Threads (2026-05-31 user thread) — proves genuine newcomer curiosity ("have any women started Kisspeptin?") rather than vendor-seeded content. (2026-05-31)

Source URLs were not recorded for these references.